The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prior 3 decades. The purpose of this program is to outline the therapies that have been approved since 2010 and focus on the oral therapies, in particular Abiraterone and Enzalutamide. A practical discussion will include the mechanisms of action, the clinical trials resulting in approval by the FDA, the indications for their use and potential side effects. I will briefly discuss resistance mechanisms including ARV 7 splice variant and will discuss combination therapies in development. I will conclude the program with strategies for sequencing the new landscape of therapeutic options. The program will include audience questions and answers.